Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition

Cornea

Volumn 30, Issue 1, 2011, Pages 60-66

  Chu, Hsiao Sang ^a   Hu, Fung Rong ^a   Yang, Chung May ^a   Yeh, Po Ting ^a   Chen, Yan Ming ^a   Hou, Yu Chih ^a   Chen, Wei Li ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

bevacizumab; corneal neovascularization; lipid keratopathy; subconjunctival injection; vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; LIPID;

ADOLESCENT; ADULT; AGED; ARTICLE; CATARACT; CHILD; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; CORNEA ULCER; DENSITY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; KERATOPATHY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHILD; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; LIPID METABOLISM; LIPID METABOLISM DISORDERS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 78650935206     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181e458c5     Document Type: Article

References (49)

1. Alfonso E, Arrellanes L, Boruchoff SA, et al. Idiopathic bilateral lipid keratopathy. Br J Ophthalmol. 1988;72:338-343.
2. Cogan DG, Kuwabara T. Lipid keratopathy and atheroma. Circulation. 1958;18:519-525.
3. Croxatto JO, Dodds CM, Dodds R. Bilateral and massive lipoidal infiltration of the cornea (secondary lipoidal degeneration). Ophthalmology. 1985;92:1686-1690.
4. Shapiro LA, Farkas TG. Lipid keratopathy following corneal hydrops. Arch Ophthalmol. 1977;95:456-458.
5. Morisawa M, Yamagami S, Inoki T, et al. Bilateral centripetal lipid keratopathy with diffuse anterior scleritis. Acta Ophthalmol Scand. 2003; 81:202-203.
6. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
7. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19:1525-1533.
8. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004; 82:557-563.
9. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
10. Berse B, Brown LF, Van de Water L, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992;3: 211-220.
11. Murata T, Ishibushi T, Ahmad K, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
12. Kunz Mathews M, Merges C, McLeod DS, et al. Vascular endothelial growth factor (VEGF) and vascular permeability change in human diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:2729-2741.
13. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.
14. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
15. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.
16. Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc. 2007;79:389-394.
17. Bock F, Konig Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246:281-284.
18. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
19. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008;27:743-745.
20. Chen WL, Lin CT, Lin NT, et al. Subconjunctival injection of Bevacizumab (Avastin) inhibits corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2009; 50:1659-1665.
21. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
22. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
23. Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea. 2009; 28:1070-1073.
24. Chen WL, Hu FR, Wang IJ, et al. Surgical results of photorefractive keratectomy with different operative modes. J Cataract Refract Surg. 2000;26:879-886.
25. Barchiesi BJ, Eckel RH, Ellis PP. The cornea and disorders of lipid metabolism. Surv Ophthalmol. 1991;36:1-22.
26. Courtice FC, Garlick DG. The permeability of the capillary wall to the different plasma lipoproteins of the hypercholesterolaemic rabbit in the relation to their size. Q J Exp Physiol Cogn Med Sci. 1962;47:221-227.
27. Walton KW. Studies on the pathogenesis of corneal arcus formation. I. The human corneal arcus and its relation to atherosclerosis as studied by immunofluorescence. J Pathol. 1973;111:263-274.
28. Walton KW, Dunkerley DJ. Studies on the pathogenesis of corneal arcus formation II. Immunofluorescent studies on lipid deposition in the eye of the lipid-fed rabbit. J Pathol. 1974;114:217-229.
29. Friedman M, Byers SO. Excess lipid leakage: a property of very young vascular endothelium. Br J Exp Pathol. 1962;43:363-372.
30. Crispin S. Ocular lipid deposition and hyperlipoproteinaemia. Prog Retin Eye Res. 2002;21:169-224.
31. Haynes WL, Proia AD, Klintworth GK. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci. 1989;30:1588-1593.
32. Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol. 1992;110:405-407.
33. Joussen AM, Germann T, Kirchhof B. Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. Graefes Arch Clin Exp Ophthalmol. 1999;237:952-961.
34. Lepri A, Benelli U, Bernardini N, et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol. 1994;10:73-80.
35. Shi W, Gao H, Xie L, et al. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci. 2006;47:3339-3344. (Pubitemid 351639695)
36. Marsh RJ, Marshall J. Treatment of lipid keratopathy with the argon laser. Br J Ophthalmol. 1982;66:127-135.
37. Marsh RJ. Lasering of lipid keratopathy. Trans Ophthalmol Soc U K. 1982;102:154-156.
38. LEsperance FA Jr. Clinical applications of the organic dye laser. Ophthalmology. 1985;92:1592-1600.
39. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41:2148-2153.
40. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
41. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19:234-238.
42. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007; 18:502-508.
43. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol. 2007; 35:494-496.
44. Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta 1 in human corneas with neovascularization. Cornea. 2000;19:526-533.
45. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419-428.
46. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
47. Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol. 2007;35:745-748.
48. Cursiefen C, Hofmann-Rummelt C, Küchle M, et al. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol. 2003;87:101-106.
49. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:33-38.